Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00002547-M01 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00002547-M01, RRID:AB_549186
- Product name
- Mouse Monoclonal Ku70/XRCC6 Antibody
- Antibody type
- Monoclonal
- Description
- IgG purified. XRCC6 - thyroid autoantigen 70kDa (Ku antigen)
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references Lysine-specific demethylase 2A enhances binding of various nuclear factors to CpG-rich genomic DNAs by action of its CXXC-PHD domain.
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
Myonuclear breakdown in sporadic inclusion body myositis is accompanied by DNA double strand breaks.
Iuchi S, Paulo JA
Scientific reports 2019 Apr 2;9(1):5496
Scientific reports 2019 Apr 2;9(1):5496
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Pinel B, Duchesne M, Godet J, Milin S, Berger A, Wager M, Karayan-Tapon L
Journal of neuro-oncology 2017 Apr;132(2):287-294
Journal of neuro-oncology 2017 Apr;132(2):287-294
DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
Bouchaert P, Guerif S, Debiais C, Irani J, Fromont G
International journal of radiation oncology, biology, physics 2012 Dec 1;84(5):1179-85
International journal of radiation oncology, biology, physics 2012 Dec 1;84(5):1179-85
Myonuclear breakdown in sporadic inclusion body myositis is accompanied by DNA double strand breaks.
Nishii M, Nakano S, Nakamura S, Wate R, Shinde A, Kaneko S, Kusaka H
Neuromuscular disorders : NMD 2011 May;21(5):345-52
Neuromuscular disorders : NMD 2011 May;21(5):345-52
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Ku70/XRCC6 Antibody (4C2-1A6) [H00002547-M01] - Analysis of XRCC6 expression in transfected 293T cell line by G22P1 monoclonal antibody (M01), clone 4C2-1A6.Lane 1: XRCC6 transfected lysate(70 KDa).Lane 2: Non-transfected lysate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Ku70/XRCC6 Antibody (4C2-1A6) [H00002547-M01] - XRCC6 monoclonal antibody (M01), clone 4C2-1A6 Analysis of XRCC6 expression in C32.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Sandwich ELISA: Ku70/XRCC6 Antibody (4C2-1A6) [H00002547-M01] - Detection limit for recombinant GST tagged XRCC6 is approximately 0.1ng/ml as a capture antibody.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunocytochemistry/Immunofluorescence: Ku70/XRCC6 Antibody (4C2-1A6) [H00002547-M01] - Analysis of monoclonal antibody to XRCC6 on HeLa cell. Antibody concentration 10 ug/ml.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: Ku70/XRCC6 Antibody (4C2-1A6) [H00002547-M01] - Analysis of monoclonal antibody to XRCC6 on formalin-fixed paraffin-embedded human breast cancer. Antibody concentration 3 ug/ml.